Archive for the ‘Lyme’ Category

“Bachelor Contestant” Has Hearing Loss Due to Lyme

https://www.yahoo.com/lifestyle/daisy-kent-actually-makes-spoiler-

Daisy Kent Actually Makes It To [SPOILER] On Joey’s ‘Bachelor’ Season

Article Excerpts:

When she was 15, she woke up and realized she couldn’t hear when her dad had trouble waking her up. “He was shaking me, and I was like, ‘This is weird,’” she told CBS 8. “I looked at him, I couldn’t hear him, then sat up and realized something was wrong with my left ear.”

Daisy said she had “a lot of high-pitched ringing and then just progressively got worse, and I couldn’t understand speech very well.” She said the experience was “super isolating” and that she felt very alone at the time.

When she was 17, she was diagnosed with Meniere’s disease, a disorder of the inner ear. At 21, tests confirmed that she also had Lyme disease, which doctors think could have potentially caused her Meniere’s disease.

Daisy ended up experiencing seizures, hair loss, joint pain, and severe dizziness, according to a video she made for NEXA Cares.

Hearing aids didn’t work for Daisy, so she ended up getting a cochlear implant, which allows people with profound hearing loss to hear better, per CBS 8.

She actually documented her experience on TikTok and built up a big following.   (See link for article, videos and pictures)

________________

For more:

Why Lyme Spirochetes Are Like Stealth Bombers

https://www.lymedisease.org/lyme-stealth-bombers/

Why Lyme spirochetes are like stealth bombers

By Lonnie Marcum
12/7/23

Borrelia burgdorferi, the bacteria that causes Lyme disease, can persist in animals and humans because it has evolved complex mechanisms to avoid the immune system.

In a 1996 interview with The Scientist magazine, Stephen Barthold, DVM, PhD, the researcher who developed the first mouse model of Lyme disease, described Borrelia burgdorferi’s ability to avoid immune detection as a form of cloaking. “It’s using some sort of stealth-bomber-type mechanism,” he said.

Since then, Professor Barthold has gone on to partner with many researchers in the pursuit of learning how B. burgdorferi causes chronic infection, including Monica Embers, PhD, from Tulane University.

Nicole Baumgarth, DVM, PhD, now the director of the Johns Hopkins Lyme and Tickborne Diseases Research and Education Institute, has years of experience collaborating with Barthold.

The latest research by Baumgarth, Barthold and others at University of California, Davis offers the science community one more clue as to how Borrelia is able to subvert the immune system leading to persistent infection in mice.

Their paper entitled, “Borrelia burgdorferi Infection–Induced Persistent IgM Secretion Controls Bacteremia, but Not Bacterial Dissemination or Tissue Burden,” has shed new light on how these pathogens persist in tissues, but present in very low numbers in the blood.

As Dr. Baumgarth tells me, “Blood is not the way Borrelia gets around the mice. Rather it migrates through tissues.”

These new findings may offer a possible explanation as to why disseminated Borrelia is both harder to treat, and so difficult to detect in blood samples.

Immune system basics

The immune system is roughly divided into two: the innate immune system and the adaptive immune system.

The innate immune system is our body’s first line of defense against pathogens and harmful substances. When working properly, it reacts immediately, but non-specifically, to all foreign invaders.

In contrast, the adaptive immune system is more targeted. It relies on prior exposure to learn and generate protective antibodies. The adaptive immune system remembers previous encounters and develops specific weapons (B-cells and T-cells) to fight each pathogen.

IgM vs IgG Antibodies

When the immune system detects any foreign substance, it produces antibodies which trigger the innate and later the adaptive immune system. IgM (immunoglobulin M) and IgG (immunoglobulin G) are two types of antibodies produced by the immune system.

IgM, the larger of these two immunoglobulins, is an early type of antibody to emerge in the development of an immune response. It acts as the initial defense against infections and is a strong activator of the complement system immune response that helps to clear pathogens.

The complement system consists of multiple proteins (C1 to C9) that summon phagocytes to the site of infection. Phagocytes (macrophages, neutrophils, lymphocytes) are components of the innate immune system that destroy pathogens. [For a crash course on the complement system watch this video.]

IgM is very effective in the blood stream. However, the size of IgM antibodies impedes their ability to penetrate all the tissues of the body. This limits IgM’s ability to send phagocytes into deeper tissues (eg. joints, heart, brain) where infection may be hiding.

IgG, a smaller, more penetrable antibody, is produced later in the immune response. IgG levels typically increase over a longer period of time, in some cases promoting the immune system to develop long-term immunity to future infection.

Study shows Borrelia impairs immune response

This new study shows how persistent Borrelia burgdorferi triggers a prolonged initial (IgM) immune response, and can impair a secondary (IgG) immune response.

This initial (IgM) response leads to fewer Borrelia burgdorferi (Bb) in the blood stream while the infection continues to spread throughout the body.

In addition, Borrelia’s prolonged IgM response in both humans and animals leads to a reduction in antibody-mediated clearance of the infection from deeper tissues.

The authors state, “Together the data demonstrated that IgG, but not IgM, is critical for the long-term control of B. burgdorferi tissue burden or disease induction. Despite that, Borrelia tissue dissemination in mice appeared very little affected by the rate of bacteremia, suggesting the B. burgdorferi main mode of dissemination in mice occurs by means other than via the blood.”

How IgM causes false-negatives

This research has shown that the standard definition of IgM as an acute response versus IgG as chronic response may be problematic in the classification of Lyme disease.

The Lyme disease Western Blot detects IgM and IgG responses to specific proteins found on Borrelia burgdorferi—for example: OspC (band 23-25), OspA (band 31), OspB (ban 34), BmpA protein (band 39), and flagellin protein (band 63-93).

In people with healthy immune systems, the Lyme disease IgM is normally detectable within a couple of weeks after infection, typically peaking around 4-6 weeks, then slowly declining over the next several months. The IgG begins around 4-6 weeks, peaking around 4-6 months, then slowly declining over the next several years.

Unfortunately, people who are immune-compromised, and/or fighting more than one infection (co-infection), may never develop a robust IgG response. The lack of the IgG response also prevents the immune system from finding and clearing bacteria embedded within deeper tissues, further impairing the healing process.

 In the experimental Bb mouse model, despite extensive antibiotic treatment, IgM production continued for months. This is consistent with human Lyme disease studies demonstrating continued IgM response as long as 10 years, even in patients treated with antibiotics.

As the authors state, this is “a remarkable observation, given the short half-life of IgM, considered to be <24 hours.” Meaning a prolonged IgM is likely coming from the immune system reacting to persistent Borrelia.

The continued production of IgM in the blood stream may explain why Borrelia is so difficult to detect in blood samples.

And because the CDC discredits the presence of IgM after four weeks, the prolonged IgM is likely contributing to the high rate of false-negative standard tests for Lyme disease.

Per the CDC website, “the IgM Western Blot test result is only meaningful during the first four weeks of illness. If you have been infected for longer than 4 to 6 weeks and the IgG Western Blot is still negative, it is highly likely that the IgM result is incorrect (e.g., a false positive). This does not mean that you are not ill, but it does suggest that the cause of illness is something other than the Lyme disease bacterium.”

We now have evidence that this is simply not true in all cases.

Difficult to Detect

In 2019, I attended a vector-borne disease conference at University of California, San Francisco. While there, *Dr. Charles Chiu explained how his powerful direct detection DNA sequencing system—able to detect thousands of pathogens—was just not finding enough Borrelia burgdorferi in the blood stream of humans to work effectively. (See my live tweets of Chiu’s presentation here.)

I was just baffled how such a powerful tool could not consistently detect Lyme disease in humans. Now, knowing that IgM remains in the blood stream longer, keeping the bacteria numbers low, may help us understand this phenomenon.

The fact that the prolonged IgM reduces the presence of Bb in the blood stream helps to explain why next-generation serologic tests using direct detection of DNA or proteins may not be able to detect Bb in patients who are suffering from chronic Lyme disease.

[*Since then Dr. Chiu has gone on partner with Johns Hopkins University where they have developed a next-generation gene sequencing technique, called RNA-seq, to map the immune response to infection. And most recently Chiu has partnered with Columbia University to open the first West Coast Center for the Clinical Trials Network.]

Immune Disruption

Also covered in Baumgarth’s paper is another strategy Bb has developed to evade the immune system. Within 24 hours after the tick bite, Bb quickly invades and is detectible in the lymph nodes nearest the site of infection.

On the surface, this seems counterintuitive, as the lymph nodes contain many life-saving immune cells.

However, once Bb is in the lymph nodes, the spirochetes induce a signal that disrupts the “germinal centers” within the lymph node architecture. Ultimately, this alters the adaptive immune response of the lymphatics and impairs the immune system by limiting memory B and T cell production.

In addition, new research from Johns Hopkins has shown that Bb impairs dendritic cells. Dendritic cells are a type of immune cell spread throughout the body. Once activated, dendritic cells migrate to the lymph nodes, where they activate the adaptive immune response. Bb’s alteration of the dendritic cells also impairs the formation of memory B and T cells.

When the immune system functions properly, IgM is produced and triggers an immune response that is good at controlling bacteremia in the blood stream. From there, an IgG response is required to control dissemination outside the blood stream.

IgM and IgG also help to trigger macrophages, a type of white blood cell that envelops and destroys pathogens. The lack of this secondary IgG response prevents macrophages from getting the message to enter and clear Bb infection from deeper tissues—which contributes to persistent infection outside the bloodstream.

Conclusion

In conclusion, the authors “propose that the continued production of immune IgM is a manifestation of B. burgdorferi mediated B cell response subversion and represents an immune evasion strategy of B. burgdorferi. It may promote B. burgdorferi dissemination out of the blood and into the skin, where it can remain until attachment and bite of a tick will induce it to migrate toward the site of the tick bite.”

I was always told Bb likes to leave the blood stream and hide in zones of the body where it is protected from the immune system. This new study shows how Bb actually uses our own immune system to aide in its ability to hide. This strategy allows Bb to survive and attain its ultimate goal— which is not to kill the host, but to get picked up by another tick and spread to another host.

Over 40 years since the discovery of the spirochete responsible for Lyme disease, we are inching closer to understanding how Borrelia burgdorferi suppresses and evades the immune system.

LymeSci is written by Lonnie Marcum, a physical therapist and mother of a daughter with Lyme. She served two terms on a subcommittee of the federal Tick-Borne Disease Working Group. Follow her on Twitter: @LonnieRhea  Email her at: lmarcum@lymedisease.org.

Reference

Hastey CJ, Olsen KJ, Elsner RA, Mundigl S, Tran GVV, Barthold SW, Baumgarth N. Borrelia burgdorferi Infection-Induced Persistent IgM Secretion Controls Bacteremia, but Not Bacterial Dissemination or Tissue Burden. J Immunol. 2023 Nov 15;211(10):1540-1549. doi: 10.4049/jimmunol.2300384. PMID: 37782044.

_______________

For more:

Methylene Blue For Tick-borne Infections & More

https://www.treatlyme.net/guide/methylene-blue-for-lyme-and-bartonella

Mighty Methylene Blue for Tick-borne Infections and More

By Dr. Marty Ross

Methylene Blue for Lyme and Bartonella Persisters

Methylene Blue Actions–What All The Buzz is About

Methylene blue is a repurposed prescription medicine that has many health benefits. Methylene blue

  • kills Bartonella and Borrelia,
  • improves fatigue and mitochondria dysfunction,
  • fixes cognitive dysfunction and brain fog,
  • lifts depression, and
  • treats methemoglobinemia (this is what it is approved to treat).

All About Methylene Blue for Lyme and Bartonella

Marty Ross, MD discusses key facts, risks, and benefits of using methylene blue to treat Lyme and Bartonella.  (See top link for article and video for how to build a MB treatment)

______________

Important note:

Caution!

Before starting methylene blue check a glucose 6 phosphate dehydrogenase (G6PD) blood test.  If you have low levels of G6PD, methylene blue could break your red blood cells apart.

If you are on anti-depression medicines or other medicines that raise serotonin, you should also use Methylene blue with caution. Here is a complete list of medicines that the United States Food and Drug Administration (FDA) advises using with caution when using Methylene blue.

In my practice, I have used Methylene blue with a number of these restricted medicines, but I always try to use them at no more than one-half the upper dose limit. Talk to your healthcare provider before taking Methylene blue with these restricted medications.

For more:

Federal Oversight of Lab Tests Part 2

Go here for Part 1.

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/

Medscape: New Federal Oversight of Lab Developed Tests (Part 2)

Carl Tuttle

Hudson, NH, United States

DEC 4, 2023 — 

Follow-up letter to Auwaerter’s Commentary on Medscape:

New Federal Oversight of Lab Developed Tests
https://www.medscape.com/viewarticle/997365

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: “pauwaert@jhmi.edu” <pauwaert@jhmi.edu>, “pgauwaerter@gmail.com” <pgauwaerter@gmail.com>
Cc: “aaguilar@webmd.net” <aaguilar@webmd.net>, “DFlapan@Medscape.net” <DFlapan@Medscape.net>, “lkane@medscape.net” <lkane@medscape.net>, “gamiller@medscape.net” <gamiller@medscape.net>, “dolmos@webmd.net” <dolmos@webmd.net>, “sarah.wright@webmd.net” <sarah.wright@webmd.net>, “editor2@webmd.net” <editor2@webmd.net>, “dqhh@westchestergov.com” <dqhh@westchestergov.com>, “jmm2@uab.edu” <jmm2@uab.edu>, “sarah.long@drexelmed.edu” <sarah.long@drexelmed.edu>, “scalderwood@partners.org” <scalderwood@partners.org>, “cbusky@idsociety.org” <cbusky@idsociety.org>, “tjohnson@idsociety.org” <tjohnson@idsociety.org>
Date: 11/01/2023 9:04 AM EDT
Subject: Re: Medscape: New Federal Oversight of Lab Developed Tests

“I often see patients who are concerned they might have Lyme disease, or they’ve been told by other physicians that they have a tickborne or multiple infections. I’ve had patients who claim to have five or six infections: Lyme disease, Babesia, Bartonella, Mycoplasma, or Epstein-Barr virus. -Dr. Paul Auwaerter/Medscape

Dr. Auwaerter,

The following recent study (15 Aug 2023) shows that “multiple tickborne infections” are common as a third of these 140 individuals had more than just Lyme disease. Only 52% of patients recalled having a tick bite, while 46% did not exhibit a bull’s-eye rash.

My inquiry to you that has gone unanswered:

What “FDA approved Tick-Borne Disease Panel” are you recommending so as not to miss any of these infections?

A Longitudinal Study of a Large Clinical Cohort of Patients with Lyme Disease and Tick-Borne Co-Infections Treated with Combination Antibiotics
https://www.mdpi.com/2076-2607/11/9/2152

Summary By Dr. Daniel Cameron:
https://danielcameronmd.com/how-effective-is-combination-antibiotic-treatment-for-tick-borne-infections/

In their article “A Longitudinal Study of a Large Clinical Cohort of Patients with Lyme Disease and Tick-Borne Co-Infections Treated with Combination Antibiotics” Xi and colleagues looked at 140 individuals who tested positive for tick-borne infections (TBI) with 33% of those patients infected with multiple TBIs.¹

The authors found that out of the 140 participants:

-93 (66.43%) had positive antibody responses to one tick-borne infection
-83 (59.29%) were positive for Borrelia
-7 (5.00%) were positive for Rickettsia
-1 (0.71%) each for either Babesia, Bartonella, or Ehrlichia

The remaining 47 (33.57%) patients were infected with multiple tick-borne infections, including Borrelia, Babesia, Bartonella, Ehrlichia and Rickettsia.

The majority of patients were treated with a triple antibiotic combination regimen.

Most of the participants received 500 mg cefuroxime, 300 mg rifampicin, and 300 mg lymecycline. Treatment duration ranged between 12 and 40 weeks.

In the first follow-up visit with 118 patients, 59% reported having pain and 41% had neurological symptoms. Meanwhile, there was continued improvement in patient symptoms at the second follow-up visit. Out of 101 patients, 41% reported having pain and 30% had neurological symptoms.

“There were statistically significant reductions in the incidence of pain and neurological symptoms between follow-ups,” the authors wrote.

“Thus, our study demonstrates that combination antibiotics effectively relieve TBI symptoms with good patient tolerance.”

According to the survey, 52% of patients recalled having a tick bite, while 46% did not exhibit a bull’s-eye rash.

The patients exhibited significant improvements in their health status during the first and second follow-up visits.

“The three most common symptoms reported by the patients were pain, fatigue, and neurological symptoms, such as a tingling sensation in the limbs and memory defects,” the authors wrote.

At the second follow-up visit, “The number of patients suffering from pain, neurological symptoms, and fatigue decreased by 41.43%, 37.50%, and 17.54%, respectively,” according to the authors.

The improvement in pain and neurological symptoms was significant but fatigue continued to be problematic for patients.

Authors Takeaways:

“Our study established that most patients in this cohort were infected with the Borrelia burgdorferi species, and about a third had co-infections with other tick-borne pathogens.”

“Approximately half of the patients recalled receiving a tick bite and developing a bull’s-eye rash.”

“Pain, fatigue, and neurological symptoms were among the most common persistent symptoms.”

Dr. Auwaerter,
 
What FDA approved Tick-Borne Disease Panel are you recommending so as not to miss any of these infections?

On 10/30/2023 10:21 AM EDT CARL TUTTLE <runagain@comcast.net> wrote:

Dr. Auwaerter,

Let me remind you that as Vice Chair representing the IDSA Foundation, you are required to respond to inquiries regarding any statements you make in public otherwise your credibility/integrity is in question.

Carl Tuttle

______________

And BOOM! Carl knocks the opponent out of the ring.

The Potential Benefits of Proteolytic Enzymes to Help Manage Rheumatoid Arthritis

https://popularrationalism.substack.com/p/the-potential-benefits-of-proteolytic?

The Potential Benefits of Proteolytic Enzymes to Help Manage Rheumatoid Arthritis

People with RA often have restricted diets. Check this out!

Rheumatoid Arthritis (RA) is a chronic autoimmune disorder that predominantly affects the synovial joints, leading to progressive joint destruction and disability. Traditional treatment modalities have primarily focused on anti-inflammatory medications and immunosuppressants. However, the exploration of complementary therapies, such as proteolytic enzymes, has gained momentum in recent years. This article aims to provide a comprehensive overview of the potential benefits of proteolytic enzymes in managing RA, backed by scientific evidence and clinical trials.

What are Proteolytic Enzymes?

Proteolytic enzymes, also known as proteases or peptidases, are enzymes that catalyze the breakdown of proteins into smaller peptides or amino acids. They are naturally occurring enzymes found in the digestive system, certain foods, and available as supplements. The enzymes work by breaking down protein structures, which can be beneficial in inflammation and tissue damage. They have a wide range of medical applications, from aiding digestion to wound healing1.

Key ReferenceSerratiopeptidase: Insights into the therapeutic applications

(See link for article)

________________

**Comment**

This website has posted on proteolytic enzymes (PE) for years.  They do so many beneficial things, every Lyme/MSIDS patient should learn about them and consider adding them to their regimen.

The article states that proteolytic enzymes have been studied for their anti-inflammatory effects as well as their ability to reduce pain and improve mobility – all of which are often issues with Lyme/MSIDS patients.  It also states that conventional treatments for RA come with a host of side effects while PE are safer and more cost effective.  RCTs are still needed to establish long-term safety and efficacy.

For more: